AbbVie

AbbVie Cerevel acquisition closes in $8.7B neuroscience deal

immunology · 6 min

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics, paying $45.00 per share in cash. The deal adds neuroscience assets as investors watch emraclidine, pipeline execution, and future filing catalysts.

AbbVie closes $8.7B Cerevel deal as neuroscience pipeline expands

U.S. Federal Trade Commission · immunology · 5 min

AbbVie completed its $8.7 billion acquisition of Cerevel Therapeutics on August 1, 2024, after U.S. Federal Trade Commission review. The deal adds Cerevel assets to AbbVie’s neuroscience pipeline and sets up follow-on readouts to watch.

AbbVie Elahere FDA Full Approval Analysis

FDA · rare blood cancers · 6 min

Structured plan for AbbVie Secures FDA Approval for ImmunoGen's Elahere

AbbVie Plans Layoffs: Implications for the Pharma Industry

FDA · 6 min

Structured plan for AbbVie Plans Layoffs: Implications for the Pharma Industry

FDA OK for Pivekimab Sunirine-pvzy (Decnupaz)

FDA · blastic plasmacytoid dendritic cell neoplasm · 5 min

The US FDA has approved AbbVie's antibody-drug conjugate, Decnupaz (pivekimab sunirine-pvzy), for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This marks AbbVie's first ADC entry in the blood cancer space and the first ADC approval for this ultra-rare indication.

UCB's Bimzelx vs. AbbVie's Skyrizi: Psoriatic Arthritis Competitive Landscape

FDA · psoriatic arthritis · 8 min

UCB's Bimzelx has demonstrated a competitive advantage over AbbVie's Skyrizi in head-to-head psoriatic arthritis trials. This analysis explores the implications for the competitive landscape and pharmaceutical business development.

UCB's Bimzelx Triumph: Psoriatic Arthritis Market Implications and Competitive Landscape

FDA · psoriatic arthritis · 8 min

UCB's Bimzelx (bimekizumab) has secured significant approvals for psoriatic arthritis, demonstrating strong efficacy in head-to-head trials. This success reshapes the competitive landscape and presents key opportunities and challenges for pharmaceutical business development and investment.

UCB's Bimzelx Triumphs Over AbbVie's Skyrizi in Psoriatic Arthritis

FDA · psoriatic arthritis · 7 min

UCB's Bimzelx has shown superior efficacy compared to AbbVie's Skyrizi in treating psoriatic arthritis, marking a significant milestone in the competitive landscape. This article analyzes the implications for pharmaceutical business development teams.

AbbVie and GSK's Rise in Patient Reputation: Insights for Pharma

2 min

AbbVie and GSK have made significant strides in patient reputation in the UK. This article explores the implications for the pharmaceutical industry.

Big Pharma Q1 Growth Insights: Lilly, AbbVie, J&J, AZ Lead the Charge

3 min

This article analyzes the recent Q1 growth trends in Big Pharma, focusing on key players and their market implications.